Article and Video CATEGORIES

Cancer Journey

Search By

2020 MELANOMA - MCKEAN - Current Status of Sentinel Lymph Node Mapping & Completion Lymphadenectomy
dbrock
2020 MELANOMA Updates - Current Status of Sentinel Lymph Node Mapping & Completion Lymphadenectomy
Author
GRACE Videos and Articles
Image
GRACE is excited to bring you a new series on current updates in Melanoma Treatment.

Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma service at Memorial Sloan Kettering and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University School of Medicine in Easton, PA joined GRACE to discuss current updates in treatment for Melanoma.

In this video, Dr. McKean discusses the current status of sentinel lymph node mapping and completion lymphadenectomy.

 

A huge thank you to our sponsor, Merck!

Thank you Merck!

 

 To join the conversation, visit https://cancergrace.org/forum.

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on